抑制MEK和ATR对由Mll-Af4和活化Ras驱动的B细胞急性淋巴细胞白血病模型有效
研究建立由Mll-Af4与活化突变N-Ras G12D协同驱动的高度侵袭性、可连续移植的小鼠B-ALL模型,并在小鼠及患者来源异种移植模型中证实双重靶向Mek和Atr通路具有强效协同的临床前疗效,提示该联合方案可能用于治疗携带这两种突变的患者。
要点
- 表达活化突变N-Ras G12D与Mll-Af4协同可在小鼠中产生高度侵袭性、可连续移植的B-ALL。
- 在携带两种突变的小鼠及患者来源异种移植模型中,双重靶向Mek和Atr通路显示强效协同的临床前疗效。
- 作者认为该联合方案可能用于治疗携带这些突变的患者,该小鼠模型可作为该亚型发病机制与药物发现的临床前平台。
核心结论
- 双重靶向Mek和Atr通路在携带Mll-Af4与N-Ras G12D突变的小鼠及患者来源异种移植模型中显示强效协同的临床前疗效。
- 作者认为该联合方案可能用于治疗携带这些突变的患者。
- Mll-Af4/N-Ras B-ALL小鼠模型是探索该疾病亚型分子与遗传发病机制及发现新治疗策略的临床前平台。
研究设计与样本
- 研究建立表达活化突变N-Ras G12D与Mll-Af4的小鼠B-ALL模型,并在小鼠及患者来源异种移植模型中测试小分子抑制剂的敏感性。
主要发现
- 表达活化突变N-Ras G12D与Mll-Af4协同产生高度侵袭性、可连续移植的B-ALL。
- 在携带两种突变的小鼠及患者来源异种移植模型中,双重靶向Mek和Atr通路显示强效协同的临床前疗效。
- 既往对突变MLL-r B-ALL中RAS通路下游效应分子的单药靶向抗白血病效应有限且不持久。
关键数值与推荐
- 在携带Mll-Af4与N-Ras G12D两种突变的小鼠及患者来源异种移植模型中,双重靶向Mek和Atr通路显示强效协同的临床前疗效。
临床怎么用
- 作者认为双重靶向Mek和Atr通路的联合方案可能用于治疗携带MLL-AF4与活化RAS突变的B-ALL患者。
- 该Mll-Af4/N-Ras B-ALL小鼠模型可作为该疾病亚型分子与遗传发病机制研究及新治疗策略发现的临床前平台。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infant B-cell acute lymphoblastic leukemias (B-ALLs) that harbor MLL-AF4 rearrangements are associated with a poor prognosis. One important obstacle to progress for this patient population is the lack of immunocompetent models that faithfully recapitulate the short latency and aggressiveness of this disease. Recent whole-genome sequencing of MLL-AF4 B-ALL samples revealed a high frequency of activating RAS mutations; however, single-agent targeting of downstream effectors of the RAS pathway in these mutated MLL-r B-ALLs has demonstrated limited and nondurable antileukemic effects. Here, we demonstrate that the expression of activating mutant N-Ras G12D cooperates with Mll-Af4 to generate a highly aggressive serially transplantable B-ALL in mice. We used our novel mouse model to test the sensitivity of Mll-Af4/N-Ras G12D leukemia to small molecule inhibitors and found potent and synergistic preclinical efficacy of dual targeting of the Mek and Atr pathways in mouse- and patient-derived xenografts with both mutations in vivo, suggesting this combination as an attractive therapeutic opportunity that might be used to treat patients with these mutations. Our studies indicate that this mouse model of Mll-Af4/N-Ras B-ALL is a powerful tool to explore the molecular and genetic pathogenesis of this disease subtype, as well as a preclinical discovery platform for novel therapeutic strategies.
引用
- Chu SH, Song EJ, Chabon JR, et al. Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. Blood Adv. 2018. PMID: 30266823. doi:10.1182/bloodadvances.2018021592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。